In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC by Heavey, Susan et al.
Oncotarget79526www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 48
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK 
co-targeted inhibition strategy in NSCLC
Susan Heavey1, Sinead Cuffe1, Stephen Finn1, Vincent Young2, Ronan Ryan2, 
Siobhan Nicholson3, Niamh Leonard3, Niall McVeigh1, Martin Barr1, Kenneth 
O’Byrne4, Kathy Gately1
1Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
2Department of Cardiothoracic Surgery, St. James’s Hospital, Dublin, Ireland
3Department of Histopathology, St James Hospital, Dublin, Ireland
4Cancer and Ageing Research Program, Institute of Health and Biomedical Innovation at the Translational Research Institute 
(TRI), Queensland University of Technology, Brisbane, Australia
Correspondence to: Susan Heavey, email: heaveys@tcd.ie
Keywords: PI3K, MEK, NSCLC, lung, co-target
Received: September 29, 2015    Accepted: September 12, 2016    Published: October 19, 2016
ABSTRACT
Clinical PI3K inhibition has been somewhat disappointing, due to both inadequate 
patient stratification and compensatory cell signalling through bypass mechanisms. As 
such, investigation of PI3K-MEK co-targeted inhibition has been recommended. With 
high mortality rates and a clear need for new therapeutic intervention strategies, non-
small cell lung cancer (NSCLC) is an important setting to investigate the effectiveness 
of this approach.
Here, 174 NSCLC tumours were screened for 150 mutations by Fluidigm 
technology, with 15 patients being profiled for phosphoprotein expression. The effects 
of GDC-0941 (a pan PI3K inhibitor), GDC-0980 (a dual PI3K/mTOR inhibitor) and 
GDC-0973 (a MEK inhibitor) alone and in combination were assessed in 3 NSCLC cell 
lines.
PIK3CA was mutated in 5.17% of NSCLC patients. GDC-0941 and GDC-0980 
treatment induced anti-proliferative and pro-apoptotic responses across all NSCLC 
cell lines, while GDC-0973 treatment induced only anti-proliferative responses. GDC-
0980 and GDC-0973 combined treatment led to significant increases in apoptosis and 
synergistic reductions in proliferation across the panel of cell lines.
This study found that the PI3K/MEK co-targeted inhibition strategy is synergistic 
in all 3 molecular subtypes of NSCLC investigated. Consequently, we would advocate 
clinical trials for NSCLC patients combining GDC-0980 and GDC-0973, each of which 
are separately under clinical investigation currently.
INTRODUCTION
Lung cancer incidence and treatment strategies
In 2013, lung cancer was the leading cause of 
cancer related death in men, accounting for 1.3 million 
male deaths worldwide, along with 535,000 female deaths 
[1]. This study focuses on Non-Small Cell Lung Cancer 
(NSCLC), which accounts for 80% of lung cancers.
Several key “driver” genes are mutated in NSCLC 
including, epidermal growth factor receptor (EGFR), 
anaplastic lymphoma kinase (ALK), KRAS, human 
epidermal growth factor receptor 2 (HER2), v-raf murine 
sarcoma viral oncogene homolog B1 (BRAF), MET, 
phosphatidylinositol 3-kinase catalytic α (PIK3CA), AKT 
and mitogen-activated protein kinase kinase 1 (MAP2K1). 
These aberrant genes are obvious targets for inhibition.
PI3K signalling and aberrations
PI3K-AKT-mTOR signalling is known to play 
a role in carcinogenesis and tumour progression, and 
mutations have been reported in PIK3CA in a range 
of human cancers. These PIK3CA mutations most 
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frequently affect residues Glu542 and Glu545 encoding 
the catalytic domain, and His1047 encoding the kinase 
domain [2]. PIK3CA mutation rates vary widely across 
different cancer types, being reported in 2-7% of lung 
cancers but up to 40% of breast and colorectal cancers 
[3, 4]. It should be noted that even though mutation rates 
are lower in lung cancer, this would still represent 32,000 
– 112,000 patients diagnosed annually, and as such any 
therapeutic intervention strategies based on this mutation 
would be applicable to a large cohort of patients. 
Activation of mTOR, AKT and loss of PTEN have each 
been associated with a poorer prognosis in lung cancer 
patients [5, 6], however an association between PIK3CA 
mutation status and prognosis has been controversial 
[6]. It has been hypothesized that a portion of PIK3CA-
mutant lung cancers could be dependent on PIK3CA as 
a driver oncogene, whereas in other cases, the PIK3CA 
mutation may modulate the effect of another oncogenic 
process [7].
PI3K pathway signalling is complex, with multiple 
growth factor receptors capable of activating the 
pathway. Activation of this pathway is associated with 
resistance to chemotherapy, immunotherapy and targeted 
therapies [4], and as such it is crucial that improved 
targeting strategies are developed to thwart PI3K 
signalling. One method of achieving this may be the 
utilization of horizontal or vertical co-targeted inhibition 
strategies. AKT-mTOR signalling can be activated 
due to the extensive cross-talk with other intracellular 
signalling pathways and multiple levels of redundancy, 
as well as mutation in AKT or loss of PTEN. As such it 
is plausible that the pathway can be activated in patients 
in the absence of PIK3CA mutation, as has been seen in 
breast cancer [8]. Moving forward, patient stratification 
through alternate methods may be preferable to the 
PIK3CA mutation approach, such as expression of key 
PI3K pathway proteins mTOR, pAKT or loss of PTEN.
Targeting the PI3K pathway in lung cancer
Activation of the PI3K-AKT-mTOR pathway is 
associated with all eight hallmarks of cancer, and has 
been shown to correlate with a poorer prognosis in 
NSCLC and other cancers [4, 5]. Inhibitors of class I 
PI3Ks, AKT and mTOR have been investigated in both 
the laboratory and clinical settings, and more recently 
dual PI3K-mTOR inhibitors and isoform specific PI3K 
inhibitors have been developed and are in early stage 
clinical trials [4]. Since the PI3K-AKT-mTOR can also 
become activated in the absence of PIK3CA mutation, 
for example through loss of PTEN, or mutations in 
AKT and MTOR, it is hoped that the clinical activity of 
PI3K inhibitors may not be limited to PIK3CA mutant 
tumours. In September 2015, the results of a Phase II 
trial of pan-PI3K inhibitor Buperlisib were published, 
where the trial did not meet its primary objective. Here 
it was determined that PI3K activation may not be the 
oncogenic driver in NSCLC, and as such PI3K inhibition 
may not be effective as a monotherapy in this setting. The 
authors recommend a co-targeted inhibition approach 
moving forward, where other oncogenic pathways are 
targeted alongside the PI3K pathway in NSCLC [9].
A number of pan-Class I PI3K inhibitors have been 
investigated in both the laboratory and clinical settings, 
with varying levels of success. GDC-0941 is a pan PI3K 
inhibitor which will be investigated in this study, and 
which is currently being investigated in clinical trials [10, 
11]. Preclinical data has supported PIK3CA mutations and 
PTEN loss as predictive biomarkers of response to the 
drug in lung, breast, and other solid tumours [12-14]. To 
date, 13 trials involving GDC-0941 are ongoing, mainly in 
NSCLC and breast cancer.
Dual targeted inhibition of PI3K and mTOR is hoped 
to provide superior inhibition of PI3K pathway signalling, 
as this strategy can prevent feedback activation of mTOR 
in response to PI3K inhibition. GDC-0980 is a dual PI3K-
mTOR inhibitor which is investigated in-depth in this study. 
The drug demonstrated excellent downstream inhibition of 
the PI3K pathway in vitro, with the strongest effects being 
observed in lung, breast and prostate cancer cell lines [15]. 
There are 12 trials ongoing for this drug, with Phase I trials in 
solid tumours and Phase II studies in endometrial carcinoma, 
renal cell carcinoma, prostate cancer and breast cancer.
One major mechanism of resistance to targeted 
inhibition lies in the ability of a cancer cell to utilise 
an alternative pathway as a bypass track, to maintain 
or regain oncogenic signalling. Several strategies have 
been investigated in order to pre-empt this mechanism 
of resistance, most of which involve co-targeting the 
PI3K pathway with either a growth factor receptor, 
or an alternative intracellular signalling protein. 
KRAS is commonly mutated in NSCLC (~20%-30% 
in adenocarcinoma,[16]), with an estimated 70% of 
lung tumours displaying RAS-RAF-MAPK pathway 
activation [17]. Since KRAS activation stimulates 
signalling through both the PI3K and MEK pathways, 
there have been several studies investigating the 
efficacy of co-targeting the PI3K and MEK pathways 
in NSCLC [18]. A phase I trial is currently recruiting 
patients with solid tumours for combination treatment 
with PI3K pathway inhibitor BKM120 and MAPK 
pathway inhibitor MEK162 [19]. A Phase I trial has 
recently been completed [20] which investigated the 
combination of GDC-0941 with GDC0973 in solid 
tumours. There has been no study to date in the clinical 
setting combining GDC-0980 with GDC-0973, which 
we hypothesize may provide a superior blockade of 
oncogenic signalling. One previous publication has 
investigated the combination of these two drugs in 
vivo, where it was observed that intermittent dosing of 
the two drugs led to increased anti-tumour efficacy in a 
melanoma xenograft model [21].
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RESULTS
PI3K pathway activation in NSCLC patients
DNA was isolated from 175 NSCLC FFPE patient 
samples and screened for 150 clinically relevant mutations 
in 13 genes using Fluidigm technology. The genes included 
were: EGFR, PIK3CA, KRAS, BRAF, NRAS, AKT1, 
FLT3, HRAS, KIT, MET, JAK2, MYD88 and ERBB2. 
PIK3CA was mutated in 5.17% of patient samples (9 
patients; 4: E545K, 2: H1047R, 1: H1047L, 1: G1049R 
and 1: E542K). None of these 9 patients bore concomitant 
mutations except for 1 patient who bore a PIK3CA mutation 
(H1047R) and an EGFR mutation (L858R).
PIK3CA mutation status was not found to 
correlate with survival (median survival 1147 days 
in wild-type versus 1149 days in mutant, p=0.9697). 
Protein was isolated from 15 NSCLC patient matched 
tumour and normal fresh tissue samples and profiled for 
phosphoprotein expression using PathScan intracellular 
signalling arrays. Both pmTOR and pS6RP were 
significantly more highly expressed in tumour tissue than 
matched normal tissue samples (Figure 1). 4 of these 15 
patients harboured a mutation in PIK3CA, which did not 
correlate with phosphoprotein expression.
Histological and molecular subtype of NSCLC 
cell lines used in this study
Cell lines used in this study were chosen to 
represent different histological and molecular subtypes of 
NSCLC. H460 is a large cell carcinoma cell line while 
A549 and H1975 are adenocarcinoma cell lines. Molecular 
characteristics of available NSCLC cell lines as published 
in the COSMIC (Catalogue Of Somatic Mutations In 
Cancer) database were taken into account when selecting 
the panel. Based on COSMIC data, the H460 cell line 
bares mutations in both PIK3CA and KRAS, the A549 
cell line bares wild-type PIK3CA and mutated KRAS and 
the H1975 cell line bares mutated PIK3CA and wild-
type KRAS [22-24]. Cell morphology was observed by 
fluorescence microscopy. Cell lines were stained using 
Höechst nuclear stain (blue) Mitotracker mitochondrial 
stain (red) and phalloidin F-actin stain (green) and imaged 
using the InCell 1000 (Figure 2).
Gene expression in NSCLC cell lines
Gene expression was compared across H460, 
A549 and H1975 cells using two gene expression arrays 
(SABiosciences): one which profiles the expression of 
genes related to mTOR signalling, and one which profiles 
the expression of genes related to cancer drug resistance.
H460 and A549 cell lines had similar levels of 
PIK3CA, but H460 cells expressed higher levels of 
AKT1S1 (165.1 fold), AKT2 (5.42 fold), PTEN (3634.11 
fold), GSK3B (3.93 fold), MTOR (951.67 fold) and 
MAPK1 (1717.71 fold) than A549 cells, and lower levels 
of AKT3 (-36.56 fold) among others (Supplementary 
Figure S1). Similarly, H1975 cells expressed higher levels 
of PIK3CA (2.33 fold), AKT1S1 (130.99 fold), AKT2 (3.48 
fold), PTEN (1055.37 fold), GSK3B (6.12 fold), MTOR 
(1015.72 fold) and MAPK1 (2447.82 fold) than A549 
cells, and lower levels of AKT3 (-4396.99 fold) than A549 
cells (Supplementary Figure S2). H1975 cells expressed 
higher levels of PIK3CA (2.44 fold) and DEPTOR (6.01 
fold) than H460 cells, but expressed lower levels of AKT3 
(-120.27 fold), PTEN (-3.44 fold) and similar levels of 
AKT1S1 (-1.26 fold), AKT2 (-1.56 fold), GSK3B (1.56 
fold), MTOR (1.07 fold) and MAPK1 (1.43 fold) as H460 
cells (Supplementary Figure S3).
H460 cells expressed higher levels of ABCB1 
(250.43 fold) and several other cancer drug resistance 
genes than A549 cells, but in general most of the human 
Figure 1: PI3K activation in NSCLC patients Phosphorylation of mTOR and pS6RP was profiled in 15 matched 
tumour and normal NSCLC patient fresh tissue samples. Intensity of expression was quantified using Image J. A Wilcoxon 
signed rank test was performed to compared tumour versus normal mean expression values.
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cancer drug resistance genes included were expressed 
more highly in A549 cells than H460 cells (Supplementary 
Figure S4). H1975 cells expressed higher levels of 
CDKN2A (362.66 fold) and several other cancer drug 
resistance genes than A549 cells, but again most genes on 
the panel were more highly expressed in A549 cells than 
H1975 cells (Supplementary Figure S5). H1975 cells also 
expressed higher levels of CDKN2A (1141.35 fold) than 
H460 cells, and expressed higher levels of ESR2 (119.11 
fold) and lower levels of ESR1 (-2221.47 fold) than H460 
cells (Supplementary Figure S6).
A number of genes were reported as having very 
large fold difference between cell lines, for example 
PPP2CA (7606.65 fold), EIF4EBP1 (2706.94 fold) and 
RHOA (3078.48 fold) (Figure 3). In such cases these 
genes are noted with an ‘A’ which refers to one out of 
the two samples not expressing the gene (or expressing it 
after the cycle threshold of 30 cycles). As such the gene is 
expressed in one cell line but not the other. The number of 
genes up/down regulated in each comparison is noted in 
each figure legend.
Anti-cancer effects of GDC-0941 and GDC-0980 
in PIK3CA mutant and wild-type NSCLC cell 
lines
Two PIK3CA mutant cell lines (H460 and H1975) 
and one PIK3CA wild-type cell line (A549) were used 
in this study. Here, the three cell lines were treated 
with either GDC-0941 or GDC-0980. Cell viability 
Figure 2: Histological and mutational characterisation of NSCLC cell lines. NSCLC cell lines used in this study were chosen 
based on their differing histological subtypes. Mutation status was obtained from the COSMIC database. Cell images were obtained using 
the InCell 1000. Each cell line was stained with Höechst blue nuclear stain, mitotracker red mitochondrial stain and phalloidin green F-actin 
stain.
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was measured qualitatively and quantitatively after 48 
hours by a multiparameter apoptosis assay (high content 
analysis), or cell proliferation was measured after 72 hours 
quantitatively by BrdU proliferation assay.
Both GDC-0941 and GDC-0980 were found to 
induce a reduction in cell viability in all three cell lines, 
as observed qualitatively (Figure 3a, Figure 4a) and 
by cell count (Figure 3b, Figure 4b). Both GDC-0941 
and GDC-0980 were found to have dose dependant 
anti-proliferative effects on all three cell lines. H1975 
cells were most sensitive to both drugs, and A549 cells 
were least sensitive to both drugs, as measured by IC50 
concentration. There was no statistically significant 
difference (i.e. p>0.05) between the anti-proliferative 
effects of the two drugs in any cell line, although 
the IC50 concentrations were lower for GDC-0980 
(Figure 5).
Anti-cancer effects of GDC-0973 in NSCLC cell 
lines
This study will investigate the effects of combining 
PI3K pathway inhibition with MEK pathway inhibition. 
As such, the effects of MEK inhibitor GDC-0973 were first 
investigated alone in H460, A549 and H1975 cells. GDC-
0973 did not appear to have a strong effect on viability 
qualitatively (Figure 6a), and did not induce a statistically 
significant reduction in cell count in any cell line (Figure 
6b). However, GDC-0973 did induce a reduction in 
proliferation in A549 and H1975 cells (Figure 7).
Co-targeted inhibition of the PI3K and MEK 
pathways in NSCLC
Due to the extensive cross-talk and feedback 
stimulation that is known to exist between the PI3K and 
MEK pathways, there has been increased interest in co-
targeting PI3K and MEK as an anti-cancer treatment. Here, 
the effects of GDC-0980 and GDC-0973 in combination 
on viability, proliferation and protein expression were 
investigated in H460, A549 and H1975 cells.
The reduction in cell viability induced by GDC-
0980 and GDC-0973 in combination was significantly 
greater than that of either drug alone in H460 and A549 
cell lines. A similar trend was observed in H1975 cells, 
though there was not a statistically significant difference 
between the effects of GDC-0980 and the mix of the two 
drugs (Figure 8).
Figure 3: The effect of GDC-0941 treatment on viability in a panel of NSCLC cells. H460, A549, and H1975 cells were 
treated at noted concentrations of GDC-0941 for 48 hours in a 96 well plate and then fixed & stained with Höechst nuclear stain, mitotracker 
red mitochondrial stain and phalloidin green F-actin stain. A. Stained plates were imaged using the InCell 1000 (10X objective, 10 fields 
per well, triplicate wells, n=3). B. Images were analysed for cell count using InCell 1000 software. Cell numbers from each treatment group 
were compared with untreated cell numbers and are represented here as % cell count compared to untreated cells, with mean ± SEM for 
treated groups. */***: p<0.05/0.001 respectively, compared to untreated cells of the same cell line.
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A BrdU proliferation assay was used to interrogate 
the interaction between GDC-0980 and GDC-0973 in the 
three NSCLC cell lines in more detail. CalcuSyn software 
was used to analyse the data, returning combination index 
(CI) values for the drug interaction at each concentration 
used, based on the Chou-Talalay equation. A CI of <1 
implies that there is a synergistic interaction between the 
two drugs, CI=1 implies an additive effect between the 
two drugs and a CI>1 implies that there is an antagonistic 
effect between the two drugs. In H460 cells, the drugs 
had a synergistic interaction at 0.1µM, 0.5µM, 1µM and 
5µM (Figure 9a). In A549 and H1975 cells, there was a 
synergistic interaction between the two drugs at 0.1µM, 
0.5µM and 1µM (CI<1, Figure 9b , Figure 9c).
Optimal treatment times and concentrations 
for assessment of protein expression in response to 
inhibition by GDC-0941, GDC-0980 and GDC-0973 
were determined by Western blot (data not shown). 
PathScan arrays were then used to profile the expression 
of 18 phosphorylated or cleaved proteins in response to 
treatment with GDC-0980 and/or GDC-0973, and at 
baseline untreated (Figure 10, Supplementary Figure S7, 
Supplementary Figure S8, Supplementary Figure S9, 
Supplementary Figure S10). pERK1/2 (Thr202/Ty204) 
expression could not be accurately determined due to 
noise from the adjacent positive control, however pERK 
expression should be reduced in response to GDC-0973 
treatment. As such, this protein was further investigated by 
use of an MSD array, which contained spots for total ERK 
and pERK (Thr202/Tyr204, Thr185/Tyr187), allowing 
quantification of percentage ERK phosphorylation in 
response to the drug. Here, ERK phosphorylation was 
shown to be significantly reduced in response to both 
GDC-0973 treatment alone, and the combination of the 
two drugs, for all three cell lines (Figure 11).
pSTAT3 (Tyr705) expression was similar across 
all cell lines. GDC-0980 treatment both alone and in 
combination with GDC-0973 led to significantly decreased 
expression of pAKT (Thr308) in H1975 cells. GDC-
0980 treatment led to significantly reduced expression 
of pAKT (Ser473) in H460, A549 and H1975 cells, 
with the effect being largest in H1975 cells. In H1975 
cells, GDC-0973 treatment led to increased expression 
of pAKT (Ser473), but combined treatment with both 
inhibitors still led to a significant reduction in expression 
of the protein. Expression of pAMPKα (Thr172) was 
similar across all treatments in all cell lines. GDC-0980 
treatment induced a reduction in pS6RP (Ser235/236) 
Figure 4: The effect of GDC-0980 treatment on viability in a panel of NSCLC cells. H460, A549, and H1975 cells were 
treated at noted concentrations of GDC-0980 for 48 hours in a 96 well plate and then fixed & stained with Höechst nuclear stain, mitotracker 
red mitochondrial stain and phalloidin green F-actin stain. A. Stained plates were imaged using the InCell 1000 (10X objective, 10 fields 
per well, triplicate wells, n=3). B. Images were analysed for cell count using InCell 1000 software. Cell numbers from each treatment group 
were compared with untreated cell numbers and are represented here as % cell count compared to untreated cells, with mean ± SEM for 
treated groups. ***: p<0.001 compared to untreated cells of the same cell line.
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expression in H460, A549 and H1975 cells. As with 
pAKT (Ser473), this effect was largest in H1975 cells. 
GDC-0973 treatment also led to reduced expression of 
pS6RP (Ser235/236) in H460 and A549 cells. GDC-0980 
induced a reduction in pmTOR (Ser2448) expression in 
H460, A549 and H1975 cells. GDC-0973 treatment also 
induced a reduction in expression of pmTOR (Ser2448) in 
H460 cells. GDC-0980 treatment (with or without GDC-
0973) led to reduced expression of pHSP27 (Ser78) in 
all three cell lines. Treatment with GDC-0973 alone led 
Figure 5: Comparison of the anti-proliferative effects of GDC-0941 and GDC-0980 in NSCLC cell lines. Cells were 
treated at noted concentrations of GDC-0941 or GDC-0980 for 72 hours, then proliferation rates were examined by BrdU incorporation 
ELISA (triplicate wells, n=3). Raw absorbance values for each treatment group were compared with untreated sample values, which were 
set to 100%. Data was then expressed as % proliferation compared to untreated cells, with mean ± SEM. Data from a) was analysed by 
linear regression and IC50 values were determined using GraphPad Prism.
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to reduced expression of pHSP27 (Ser78) in H460 and 
A549 cells but not H1975 cells. GDC-0980 treatment 
(with or without GDC-0973) led to reduced expression 
of pBAD (Ser112) in all three cell lines. Treatment with 
GDC-0973 alone led to reduced expression of pBAD 
(Ser112) in H460 cells but not A549 or H1975 cells. 
GDC-0980 treatment (with or without GDC-0973) led to 
reduced expression of pp70S6K (Thr389) in H460, A549 
and H1975 cells. Treatment with GDC-0973 alone led to 
reduced expression of pp70S6K (Thr389) in H460 cells 
but not A549 or H1975 cells. pp70S6K is a downstream 
mediator of both the PI3K and MEK pathways, which 
can be activated by either pathway. As such it would be 
hoped that the co-targeted inhibition approach would lead 
to a reduction in expression of this protein compared with 
treatment with either inhibitor alone. Here we saw that this 
was the case for H460 cells, but not either of the other two 
cell lines. GDC-0980 treatment (with or without GDC-
0973) led to reduced expression of pPRAS40 (Thr246) in 
all three cell lines. GDC-0980 treatment alone induced a 
reduction in pp53 (Ser15) expression in all three cell lines, 
and the combination of the two drugs induced a reduction 
in expression of the protein in H460 and A549 cells but 
not H1975 cells. GDC-0973 treatment also induced a 
reduction in expression of pp53 (Ser15) in A549 cells. 
pp38 (Thr180/Tyr182) expression was similar across all 
treatments in all cell lines. GDC-0980 treatment (with or 
without GDC-0973) led to reduced expression of pSAPK/
JNK (Thr183/Tyr185) in H460, A549 and H1975 cells. 
GDC-0980 treatment (with or without GDC-0973) led 
to reduced expression of PARP (Asp214 cleavage) in 
H460 cells, but not in the other two cell lines. Caspase-3 
(Asp175 cleavage) expression was similar across all 
treatments in all cell lines. GDC-0980 treatment alone 
led to reduced expression of pGSK-3β (Ser9) in H460 
and H1975 cells, and the mix of the two drugs induced a 
reduction of expression of the protein in H460, A549 and 
H1975 cells. GDC-073 treatment alone also led to reduced 
expression of pGSK-3β (Ser9) in H460 cells.
DISCUSSION
PIK3CA mutation frequency in an Irish NSCLC 
cohort
PIK3CA mutation status is known to be associated 
with PI3K pathway activation, which in turn is known 
to be involved in carcinogenesis. The PI3K pathway can 
Figure 6: The effect of GDC-0973 treatment on viability in a panel of NSCLC cells. H460, A549, and H1975 cells were 
treated at noted concentrations of GDC-0973 for 48 hours in a 96 well plate and then fixed & stained with Höechst nuclear stain, mitotracker 
red mitochondrial stain and phalloidin green F-actin stain. A. Stained plates were imaged using the InCell 1000 (10X objective, 10 fields 
per well, triplicate wells, n=3). B. Images were analysed for cell count using InCell 1000 software. Cell numbers from each treatment group 
were compared with untreated cell numbers and are represented here as % cell count compared to untreated cells, with mean ± SEM for 
treated groups.
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be activated by a number of other molecular alterations, 
most notably activation of AKT, mTOR or loss of PTEN. 
Multiple studies have investigated the value of each of 
these PI3K pathway alterations as prognostic indicators, 
with varying findings [6]. This study investigated the 
frequency of PIK3CA mutations in an Irish cohort of 
174 patients as part of a larger study being carried out by 
the European Thoracic Oncology Platform (ETOP) on a 
total of 2709 patients. PIK3CA was mutated in 5.26% of 
adenocarcinoma patients and 15.87% of squamous cell 
carcinoma patients from the Irish cohort and 4.6% of total 
ETOP cases [25]. A recent pan-PI3K inhibitor clinical 
trial found that PIK3CA mutation status is not an ideal 
method of stratifying patients for PI3K pathway targeted 
therapy [9]. As such, expression of key PI3K pathway 
phosphoproteins was profiled in 15 matched tumour and 
Figure 7: Anti-proliferative effects of GDC-0973 in a panel of NSCLC cell lines. Cells were treated at noted concentrations of 
GDC-0973 for 72 hours, then proliferation rates were examined by BrdU incorporation ELISA (triplicate wells, n=3). A. Raw absorbance 
values for each treatment group were compared with untreated sample values, which were set to 100%. Data was then expressed as % 
proliferation compared to untreated cells, with mean ± SEM. B. Data from a) was analysed by linear regression and IC50 values were 
determined using GraphPad Prism.
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normal fresh tissue samples. Both pmTOR and pS6RP 
were found to be significantly more highly expressed in 
tumour than normal tissue, and phosphoprotein expression 
did not correlate with PIK3CA mutation status here. As 
such, we hypothesize that downstream phosphoprotein 
expression profiling could be a preferable method 
of identifying tumours with elevated PI3K pathway 
activation compared with PIK3CA mutation identification 
alone, particularly in key proteins such as mTOR and 
S6RP, both of which can be activated by multiple 
redundancies and cross-talk with other pathways including 
the MEK pathway.
PIK3CA mutation status and PI3K pathway 
activation in vitro
Three cell lines were be used throughout this 
project in order to investigate the efficacy of different 
strategies for targeting the PI3K in NSCLC. These three 
cell lines were initially characterised for PI3K pathway 
mutation status and activation, which could then be 
related to the results obtained previously from NSCLC 
patient samples.
H460 cells have mutations in PIK3CA and KRAS, 
A549 cells have wild-type PIK3CA but mutated KRAS and 
IDH1 and H1975 cells have mutated PIK3CA, PIK3R1, 
CDKN2A and EGFR but wild-type KRAS. PIK3CA gene 
expression was similar across the panel of cell lines (if 
slightly higher in H1975 cells). Expression of pAKT 
(Ser473), was significantly higher in H1975 cells than 
the other two cell lines, which could be attributed to the 
two PI3K pathway mutations present in this cell line, 
and the fact that the cell line does not have a mutation in 
KRAS, implying that PI3K could potentially be the driver 
oncogene in this cell line.
Response to PI3K pathway inhibition in PIK3CA 
mutant versus PIK3CA wild-type NSCLC cell 
lines
It has been hypothesized that PIK3CA mutation 
status may serve as a predictive biomarker of response to 
PI3K targeted therapy. However, the correlation between 
PIK3CA mutation status and response to PI3K targeted 
therapy is controversial, with several other potential 
biomarkers including PTEN loss being put forward as 
Figure 8: Effects of PI3K-mTOR and MEK co-targeted inhibition on NSCLC cell viability. H460, A549 and H1975 cells 
were treated with GDC-0980 (1µM), GDC-0973 (1µM), both GDC-0980 (1µM) and GDC-0973 (1µM) or left untreated for 48 hours in a 
96 well plate and then fixed & stained with Höechst nuclear stain, mitotracker red mitochondrial stain and phalloidin green F-actin stain. 
A. Stained plates were imaged using the InCell 1000 (10X objective, 10 fields per well, triplicate wells, n=3). B. Images were analysed for 
cell count using InCell 1000 software. Treatment groups were compared with untreated cell numbers (raw data) and are represented here as 
% cell count compared to untreated cells, with mean ± SEM for treated groups. */**/***: p<0.05/0.01/0.001.
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alternatives [14]. Tumours that bear wild-type PIK3CA 
may also respond to PI3K targeted therapy, as we know 
that the pathway can be activated due to other aberrations 
such as PTEN loss, AKT or MTOR mutation.
While alterations in PIK3CA may act as driver 
mutations in some tumours, they could also act as 
passenger mutations in others. In the former case, 
constitutive activation of PI3K signalling occurs and the 
tumour is expected to be addicted to the pathway. As such, 
the tumour would respond well to PI3K targeted therapy. 
In the latter case, the PIK3CA mutation may not be 
driving tumour progression or maintenance, and as such 
either PI3K targeted therapy will be less effective, or drug 
resistance will develop more quickly as the tumour uses 
the co-existing driver mutation to overcome the effects of 
the drug.
Here we set out to investigate the effects of 
targeting PI3K in our panel of PIK3CA mutant and 
wild-type NSCLC cell lines. H1975 cells, which have 
a PIK3CA mutation as well as mutations in PIK3R1, 
EGFR and CDKN2A and no mutation in KRAS, were the 
most sensitive cell line to both PI3K pathway inhibitors, 
GDC-0941 (first generation, pan PI3K inhibitor) and 
GDC-0980 (second generation, dual PI3K-mTOR 
inhibitor), suggesting that PIK3CA may act as a driver 
mutation here. A549 cells, which bear wild-type PIK3CA 
but have a mutation in KRAS and IDH1, were the least 
sensitive to both GDC-0941 and GDC-0980, implying 
that the cell line does not rely on PI3K signalling. Due 
to the mutation in KRAS that is present in this cell line, 
it can be hypothesized that the cells are addicted to 
KRAS signalling and as such are not greatly affected 
by inhibition of PI3K. Finally, H460 cells were less 
sensitive to PI3K inhibition by GDC-0941 and GDC-
0980 than H1975 cells, despite the fact that H460 cells 
bear a mutation in PIK3CA. Here, we hypothesize that 
Figure 9: PI3K-mTOR and MEK combined inhibition induces a synergistic reduction in proliferation in NSCLC cells. 
 a. H460, b. A549 and c. H1975 cells were treated with GDC-0980, GDC-0973 or a 1:1 mix of GDC-0980 & GDC-0973 at noted concentrations 
for 72 hours. Proliferation rates were then assessed by BrdU incorportation ELISA (triplicate wells, n=3). Raw absorbance values for each 
treatment group were compared with untreated sample values, which were set to 100%. Data was then represented as absorbance (which 
correlates directly with proliferation) with mean ± SEM. d. Data was analysed using CalcuSyn software which tests for synergistic, additive 
or antagonistic drug interactions via the Chou-Talalay method. A combination index (CI) of >1 indicates an antagonistic interaction, CI = 1 
indicates an additive interaction and CI < 1 indicates a synergistic interaction. */**/***: p<0.05/0.01/0.001 respectively.
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Figure 10: The effects of co-targeting PI3K-mTOR and MEK on phosphoprotein expression in a panel of three NSCLC 
cell lines. Protein was isolated from H460, A549 and H1975 cell lines at baseline and after treatment with GDC-0980 (1µM, 4hrs), GDC-
0973 (2µM, 6hrs) and a mix of the 2 drugs using Cell Signalling lysis buffer. Intracellular signalling protein expression was explored using 
PathScan arrays (duplicate spots, n=3). Array images are shown with postive (+) and negative (-) controls identified. 1: ERK1/2 (Thr202/
Tyr204), 2:Stat1(Tyr701), 3: Stat3 (Tyr705), 4: AKT (Thr308), 5: AKT (Ser473), 6: AMPKα (Thr172), 7: S6RP (Ser235/236), 8: mTOR 
(Ser2448), 9: HSP27 (Ser78), 10: BAD (Ser15), 11: p70S6K (Thr389), 12: PRAS40 (Thr246), 13: p53 (Ser15), 14: p38 (Thr180/Tyr182), 
15: SAPK/JNK (Thr183/Tyr185), 16: PARP (Asp214), 17: Caspase-3 (Asp175), 18: GSK-3β (Ser9).
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PIK3CA is acting as a passenger mutation while the 
co-existing mutation in KRAS is driving the cell line’s 
oncogenic properties. Both GDC-0941 and GDC-0980 
do still induce anti-proliferative effects here, albeit to a 
lesser degree than in H1975 cells.
Based on these results we would advocate 
further research into the relevance of KRAS mutation 
status to PI3K/MEK pathway inhibition. In the future 
a full mutational profile of all patients that are being 
considered for PI3K targeted therapy should be carried 
out, as even in this small study differences can be seen 
in the response of different molecular subtypes to this 
form of therapy.
Pan-PI3K inhibition versus pan-PI3K-mTOR 
dual inhibition in a panel of NSCLC cell lines
First generation PI3K pathway targeted drugs 
such as GDC-0941 inhibited the class I isoforms of 
PI3K. These drugs have had some success in the clinic, 
although even where patients initially responded to 
the drugs, resistance often developed rapidly [4, 13]. 
Figure 11: Effect of GDC-0980 and/or GDC-0973 treatment on total ERK and pERK1/2 (Thr202/Tyr204, Thr185/
Tyr187) expression in a panel of NSCLC cell lines. Protein was isolated from H460, A549 and H1975 cell lines at baseline and after 
treatment with GDC-0980 (1µM, 4hrs), GDC-0973 (2µM, 6hrs) and a mix of the 2 drugs using MSD lysis buffer. Total ERK and pERK1/2 
(Thr202/Tyr204, Thr185/Tyr187) expression was explored using MSD arrays (duplicate wells, n=3). Spot intensity was quantified through 
MSD software and data were expressed as % Phosphoprotein = ((2 x Phospho-signal) / (Phospho-signal + Total signal)) x 100. Percentage 
phosphorylation was then expressed as mean ± SEM. ***: p<0.001, compared to untreated cells unless otherwise noted.
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Further advances have led to the development of dual 
PI3K-mTOR inhibitors such as GDC-0980, which are 
hypothesized to have more potent anti-cancer effects 
due to their ability to circumvent feedback stimulation 
of PI3K-AKT-mTOR signalling.
Here we set out to compare the anti-proliferative 
effects of GDC-0941 with GDC-0980 in our panel of 
three NSCLC cell lines. In all cell lines, there was no 
statistically significant difference between the anti-
proliferative effects of GDC-0941 and GDC-0980. 
However, the IC50 concentrations were lower for GDC-
0980 than GDC-0941 in all three cell lines. Based on this 
data it is clear that there is no distinguishable difference 
between the two drugs in terms of their ability to induce a 
reduction in proliferation in the cell lines, however there 
is a trend toward GDC-0980 being slightly more effective 
here in this short term assay.
MEK inhibition in a panel of NSCLC cell lines
A number of targeted inhibitors of the MEK 
pathway have been investigated in the laboratory and 
clinical settings, with particular interest in the field of 
NSCLC due to the high rate of KRAS mutations in the 
disease. However, results have been underwhelming due 
to the tendency of MEK inhibitors to induce growth arrest 
but not apoptosis [26, 27].
Here, the effects of MEK inhibitor GDC-0973 on 
viability and proliferation were assessed in H460, A549 
and H1975 cell lines. GDC-0973 treatment did not induce 
a statistically significant effect on cell viability in any 
cell line. However, the drug did induce a reduction in 
proliferation in A549 and H1975 cells. The cell viability 
assay carried out here and throughout this project is a triple 
stain High Content Analysis assay which assesses changes 
in nuclear, cytoplasmic and mitochondrial staining, here 
in response to a drug. The nuclear stain, Höechst, is used 
to determine cell count, which is graphed to give an 
indication of any reduction in cell count in response to 
a drug. This is a method of assessing drug efficacy used 
throughout the literature, for example with regard to GDC-
0941 and GDC-0980 efficacy as reported in Genentech’s 
original research [15]. The triple stain approach allows for 
qualitative assessment of the effects of the drug on cell 
morphology and the visual identification of cell death. To 
confirm the presence of apoptosis, further investigation at 
the protein level was carried out, identifying a reduction 
in pHSP27, pBAD and p53 where apoptosis is present.
H460 cells were resistant to GDC-0973 treatment, 
with an IC50 concentration two orders of magnitude 
higher than in the other two cell lines, despite bearing 
a mutation in KRAS. H460 cells were seen to express 
multidrug resistance genes ABCB1 and ABCC2 more 
highly than the other cell lines, which could contribute 
to this effect and to the underwhelming response of H460 
cells to GDC-0941 and GDC-0980.
Co-targeted inhibition of the PI3K and MEK 
pathways in NSCLC
A number of studies have been published 
investigating the effects of co-targeted inhibition of the 
PI3K and MEK pathways. Several early phase clinical 
studies are also currently underway which combine these 
two types of therapies [28-30].
Initial results have been underwhelming with 
regards to the efficacy of the strategy. In certain cases, 
results have been shown to vary, depending on the 
presence of concurrent secondary mutations [31]. Here, 
we set out to assess the effects of co-targeted PI3K and 
MEK pathway inhibition in our panel of PIK3CA wild-
type/mutant and KRAS wild-type/mutant cell lines. GDC-
0980 (dual PI3K-mTOR inhibitor) and GDC-0973 (MEK 
inhibitor) combined treatment was shown to induce 
a significant reduction in cell viability compared to 
treatment with either drug alone in H460 and A549 cells, 
with a trend towards a similar response in H1975 cells. 
Further interrogation of the interaction between the two 
drugs identified a synergistic anti-proliferative response to 
the combined treatment approach in all cell lines, at doses 
as low as 0.1µM.
A detailed investigation of the effects of the 
combined treatment approach on intracellular signalling 
proteins was carried out using PathScan arrays in order 
to elucidate the mechanisms of inhibition at play in the 
different cell lines.
H460 cells exhibited a reduction in pAKT (Ser473), 
but not pAKT (Thr308) in response to GDC-0980, 
whereas the other PIK3CA mutated cell line, H1975, 
exhibited a significant reduction in both pAKT (Ser473) 
and pAKT (Thr308) in response to the drug. This could 
partially explain the reduced efficacy of the drug in H460 
cells compared to H1975 cells. Here, H460 cells also 
exhibited a more modest reduction in pS6RP (Ser235/236) 
and pp70S6K (Thr389) than observed in H1975 cells in 
response to GDC-0980 treatment.
A549 cells exhibited a reduction in both pAKT 
(Ser473) and pAKT (Thr308) in response to GDC-0980. 
This cell line also exhibited significant reductions in 
pS6RP (Ser235/236), pmTOR (Ser2448) and pp70S6K 
(Thr389) in response to GDC-0980.
As such, this data does not offer an explanation as 
to why A549 cells are the least sensitive cell line to GDC-
0980 treatment, however we hypothesize that either the 
high expression of a panel of cancer drug resistance genes 
identified in A549 cells, or the preferential signalling 
through KRAS due to KRAS mutation may help to reduce 
the efficacy of these inhibitors.
The signal for pERK on the arrays was quite low, 
and increased exposure times were problematic due to the 
proximity of the positive control. As such, ERK inhibition 
by the two drugs alone or in combination was further 
investigated using MSD protein arrays, which allowed for 
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calculation of percentage ERK phosphorylation. Here, it 
was observed that GDC-0973 treatment led to a reduction 
in phosphorylation to ~0.2% in the three cell lines.
GDC-0973 treatment led to reduced pSTAT1 
(Tyr701) expression in the wild-type PIK3CA cell line, 
A549. Treatment with the MEK inhibitor interestingly 
also induced an increased expression of pAKT (Ser473) 
in A549 and H1975 cells, implying that these cell lines 
may utilise pAKT or pSTAT1 signalling as bypass tracks 
in order to escape MEK inhibition. This effect was not 
seen with other PI3K pathway proteins included in these 
arrays, and as such it can be assumed that the classical 
PI3K-AKT-mTOR pathway is not activated here, but 
pAKT could be maintaining oncogenic signalling through 
other pathways.
The combined treatment approach led to a 
significantly greater reduction in protein expression 
compared to treatment with either inhibitor alone in 
certain cases, as follows. pp70S6K (Thr389) expression 
was significantly reduced under treatment with both 
drugs compared to treatment with either inhibitor alone 
in H460 cells, pSAPK/JNK (Thr183/Tyr185) expression 
was significantly reduced under treatment with both drugs 
compared to treatment with either inhibitor alone in A549 
cells and pGSK-3β (Ser9) expression was significantly 
reduced under treatment with both drugs compared 
to treatment with either inhibitor alone in A549 cells. 
However, in many more cases, the combined treatment 
approach led to a significantly greater reduction in protein 
expression compared to one of the two drugs alone. As 
such, the observed synergy between the two drugs in all 
three cell lines is likely due to the combined effect of 
inhibiting several proteins in multiple pathways at the 
same time.
Data published in 2014 has suggested that the lack 
of initial success in combining PI3K and MEK inhibitors 
in the clinic may involve a failure to induce apoptosis 
via BCL-2 family proteins [27]. Here, a large panel of 
cell lines bearing a wide variety of mutations which 
closely mirrored the heterogeneity of NSCLC tumour 
types encountered in the clinic were treated with PI3K 
and MEK inhibitors in combination. The effects of the 
combination treatment varied widely across the panel 
of cell lines, typically inducing growth arrest but often 
not inducing sufficient cytotoxic effects. Restoration of 
BIM expression was shown to resensitize KRAS-mutant 
human and mouse cancer cells to combined PI3K and 
MEK inhibition, implying a role for targeting specific 
apoptotic mediators in addition to PI3K and MEK. This 
should be further investigated as a superior strategy for 
targeted therapy in NSCLC, however significant toxicity 
issues will need to be overcome in order to develop this 
as a viable strategy in the clinic. The emergence of third 
generation isoform specific PI3K inhibitors may aid in 
this endeavour, through the minimisation of off-target 
effects.
The synergistic interaction between GDC-0980 
and GDC-0973 observed in this study is promising; 
however similar studies have been brought to the 
preclinical and clinical settings during the course 
of this study with mixed and often underwhelming 
results. These two drugs have not been investigated 
in combination in a clinical setting, although other 
dual PI3K-mTOR and MEK inhibitors have been 
investigated in combination in the clinic [19, 29, 
30]. We would advocate that further preclinical and 
ultimately clinical studies are carried out to assess the 
viability of the GDC-0980 and GDC-0973 combination 
in NSCLC and potentially other solid tumours based 
on the synergy reported here. Previously published 
data has indicated a downregulation of PI3K pathway 
signalling in cisplatin-resistant NSCLC, where GDC-
0980 was shown to induce a correspondingly weaker 
effect than that seen in cisplatin sensitive cells [32]. As 
such, the PI3K-MEK combined treatment strategy may 
be of particular use in the first line setting, prior to the 
development of cisplatin resistance.
MATERIALS AND METHODS
Drugs
GDC-0941, GDC-0980 and GDC-0973 were gifted 
under a material transfer agreement from Genentech 
for use in this study, and were dissolved in dimethyl 
sulphoxide (DMSO), aliquoted and stored at -20°C.
Lung cancer cell lines
Three lung cancer cell lines were used during 
the course of this study; large cell lung carcinoma cells 
(H460), adenocarcinomic alveolar basal epithelial cells 
(A549) and adenocarcinoma cells (H1975). Cells were 
obtained from the European Culture and Tissue Collection 
(ECACC). H460 and H1975 cells were maintained in 
Roswell Park Memorial Institute (RPMI-1640) medium, 
which was supplemented with 10% (v/v) foetal bovine 
serum (FBS) and penicillin streptomycin (P/S - 5000 U/
mL penicillin, 5000 U/mL streptomycin). A549 cells 
were maintained in F-12 (Ham) medium, which was 
supplemented with 10% (v/v) foetal bovine serum (FBS), 
penicillin streptomycin (P/S - 5000 U/mL penicillin, 
5000 U/mL streptomycin), and 2 mM L-glutamine (in 
0.85% NaCl). All three cells lines are adherent and were 
incubated in vented flasks at 37ºC in 95% air, 5% CO2 
humidified atmosphere (Steri-Cycle CO2 incubator, 
ThermoForma, Marietta, OH, USA). Cell lines were 
passaged every 48-72hrs and tested for mycoplasma once 
per month by the polymerase chain reaction (PCR) method 
[33]. Cell lines sample from before, during and after the 
period during which these experiments were carried out 
were authenticated by DNA Diagnostic Centre.
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NSCLC patient mutational profiling
As part of the European Thoracic Oncology Platform 
(ETOP) Lungscape project [25] which profiled a total of 
2709 NSCLC patient tumours from 17 predominantly 
European centres, 175 Irish NSCLC tumour samples were 
profiled by Fluidigm Technology, using an allele-specific 
test covering 13 genes (150 mutations, Supplementary 
Table 1).
RT2 profiler arrays
RT2 Profiler arrays (SABiosciences) were used to 
compare gene expression across cell line samples. Each 96 
well array contains primers for 84 genes of interest along 
with 12 controls. RNA was isolated using the RNeasy 
mini kit and cDNA was synthesized using the first strand 
kit. The PCR reaction contained SYBR green mastermix, 
cDNA synthesis reaction (1µg) and molecular grade water. 
Arrays were cycled using the 7900HT qPCR machine 
(Applied Biosystems) as per manufacturer’s protocol. 
Data was analysed using SABiosciences online software 
(2.6.6).
High content analysis viability assay
Cells were triple stained (nuclear, mitochondrial 
and cytoskeletal stains), imaged and analysed in 
order to assess viability and induction of apoptosis 
both qualitatively and quantitatively. Cells were 
counted, seeded at 2000 cells per well and treated 
as noted for a period of 48 hrs. Cells were stained 
simultaneously with Höechst nuclear stain (bisbenzimide 
H33348, FlukaBiochemika, 1µM) and Mitotracker 
Red mitochondrial stain (Invitrogen, CA, USA, 
0.5µM) for 30 minutes, then washed in PBS and 
fixed in paraformaldehyde (4%, 10 minutes) before 
permeablisation (0.5% Triton-X-100 in PBS). Cells were 
then stained with Alexa Fluor 488 Phalloidin (Invitrogen, 
10µM) and imaged using the InCell Analyser 1000 (GE 
Lifesciences). Images were analysed using High Content 
Analysis (HCA) software, which quantifies multiple 
parameters including cell count, intensity of nuclear, 
mitochondrial and cytoplasmic staining, area of nucleus, 
mitochondria and cytoplasm, and nuclear/cytoplasmic 
area or intensity.
BrdU proliferation assay
Cell proliferation was measured using a Cell 
Proliferation enzyme linked immunosorbent assay 
(ELISA), BrdU (Roche Diagnostics Ltd.). This is a 
colorimetric method to quantify cell proliferation based on 
the measurement of BrdU (5-bromo-2’-deoxyuridine - a 
pyrimidine analogue) incorporation (instead of thymidine) 
during DNA synthesis in proliferating cells. Cells were 
seeded at 2000 cells per well in a 96-well plate and adhered 
overnight (o/n). Cells were treated with appropriate 
drugs for 72 hours unless otherwise noted. Following 
treatment, 10µL of a 1:1000 dilution of BrdU labelling 
solution (final concentration - 10µM) was added to each 
well and plates incubated for 4 hours at 37°C. Following 
incubation, the media was removed and the cells fixed and 
denatured with 200µL of a fixative solution for 30 minutes 
at room temperature (RT). 100µL anti-BrdU-POD (mouse 
monoclonal antibody, peroxidase-conjugated) working 
solution was added to each well for 90 minutes at RT. Cells 
were washed three times with wash buffer and 100µL of 
substrate solution was added for 5-10 minutes (or until 
colour change was sufficient for photometric detection). 
25µL 1 mM H2SO4 was added to each well to stop the 
reaction. Absorbance was measured on a Vesamax tunable 
microplate reader (Molecular Devices) at 450nm with a 
reference wavelength set to 690nm.
PathScan arrays
PathScan arrays (Cell Signalling Technologies) are 
slide based antibody arrays which were used to profile 
expression of 18 phosphorylated or cleaved proteins 
across a panel of untreated and drug treated cell line 
samples. Capture antibodies are spotted in duplicate 
onto nitrocellulose coated glass slides, with 16 arrays per 
slide allowing for simultaneous comparison of protein 
expression across 15 samples and a control. Cell line 
protein samples were prepared and quantified as per 
manufacturer’s protocol. NSCLC patient fresh tissue 
samples were stabilised immediately using ALL protect 
(Qiagen) and then protein was isolated as per CST 
guidelines. 100µL blocking buffer was added to each 
well and incubated at RT for 15 minutes on a shaker. Cell 
lysates are diluted to 1mg/mL and 75µL of this working 
solution is added per well and incubated for overnight at 
4°C on a shaker. Four 5 minute washes were carried out 
using 1X array wash buffer, and 75µL detection antibody 
cocktail was added. The slide was incubated at RT for 1 
hour on a shaker, then four further 5 minute washes were 
carried out. 75µL HRP-linked Strepdavidin was added to 
each well and incubated for 30 minutes at RT on a shaker. 
Four further 5 minute washes were carried out prior to 
incubation in LumiGlo/peroxide mix (chemiluminescent 
reagent) for the duration of slide imaging using a 
Biospectrum Imaging System (Ultra Violet Products). 
Densitometry analysis was carried out using ImageJ.
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